Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2024

21.02.2024 | Original Article

Epidemiology and Socioeconomic Impact of Pancreatic Cancer: An Analysis of the Global Burden of Disease Study 1990–2019

verfasst von: Daryl Ramai, Eric R. Smith, Yichen Wang, Yuting Huang, Itegbemie Obaitan, Saurabh Chandan, Banreet Dhindsa, Apostolis Papaefthymiou, John D. Morris

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study is to estimate the global burden of pancreatic cancer from 1990 to 2019.

Methods

We reconstructed the Global Burden of Diseases (GBD) study results for pancreatic cancer across 204 countries and territories. Our study generated estimates for key disease burden indicators, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs), and cost. Linear regression analysis of the natural logarithm of age-standardized outcomes was used to calculate annual percent change.

Results

In 2019, there were a total of 530,296 incident and 442,101 prevalent cases of pancreatic cancer, resulting in 531,107 deaths and 11.5 million DALYs lost. The age-standardized incidence and prevalence of pancreatic cancer has increased from 5.22 (95% CI 4.97–5.40) to 6.57 (CI 6.00–7.09) per 100,000 people per year, and 4.1 (95% CI 3.95–4.26) to 5.4 (CI 4.96–5.87), respectively. This equated to 10 million (95% CI 9.5 to 10.4 million) incident cases of pancreatic cancer. The number of DALYs lost as a result of pancreatic cancer was 225 million years (95% CI 216–234 million years). Mortality from pancreatic cancer increased over the study period from 3.7 (95% CI 3.54–3.83) to 6.9 (95% CI 6.36–7.32). Incidence, prevalence, DALYs, and mortality were higher in countries with a higher socio-demographic index.

Conclusions

Pancreatic cancer is rising around the world and is associated with a high economic burden. Programs aimed at reducing modifiable risk factors are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.CrossRefPubMed Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.CrossRefPubMed
2.
Zurück zum Zitat Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–502.CrossRefPubMedPubMedCentral Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–502.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159:358–62.CrossRefPubMed Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159:358–62.CrossRefPubMed
5.
6.
7.
Zurück zum Zitat Ali H, Pamarthy R, Vallabhaneni M, et al. Pancreatic cancer incidence trends in the United States from 2000–2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database. F1000Research. F1000Res. 2021;10:529. Ali H, Pamarthy R, Vallabhaneni M, et al. Pancreatic cancer incidence trends in the United States from 2000–2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database. F1000Research. F1000Res. 2021;10:529.
8.
Zurück zum Zitat GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
9.
Zurück zum Zitat GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266.
15.
Zurück zum Zitat Bennitt FB, Wozniak SS, Causey K et al. Estimating disease burden attributable to household air pollution: new methods within the Global Burden of Disease Study. The Lancet Global Health. 2021;9:S18.CrossRef Bennitt FB, Wozniak SS, Causey K et al. Estimating disease burden attributable to household air pollution: new methods within the Global Burden of Disease Study. The Lancet Global Health. 2021;9:S18.CrossRef
16.
Zurück zum Zitat Peterson HM, Flaxman AD. Meta-regression with DisMod-MR: how robust is the model? The Lancet. 2013;381:S110.CrossRef Peterson HM, Flaxman AD. Meta-regression with DisMod-MR: how robust is the model? The Lancet. 2013;381:S110.CrossRef
17.
Zurück zum Zitat G Gordon-Dseagu VL, Devesa SS, Goggins M, et al. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39. G Gordon-Dseagu VL, Devesa SS, Goggins M, et al. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39.
19.
Zurück zum Zitat Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158–1160.CrossRefPubMed Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158–1160.CrossRefPubMed
20.
Zurück zum Zitat Wang Y, Huang Y, Chase RC, et al. Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019 [published online ahead of print, 2023 Jun 9]. Gastroenterology. 2023;S0016–5085:00825–9. Wang Y, Huang Y, Chase RC, et al. Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019 [published online ahead of print, 2023 Jun 9]. Gastroenterology. 2023;S0016–5085:00825–9.
21.
Zurück zum Zitat Ramai D, Lanke G, Lai J, et al. Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study. Pancreatology. 2021;21:124–129. CrossRefPubMed Ramai D, Lanke G, Lai J, et al. Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study. Pancreatology. 2021;21:124–129. CrossRefPubMed
22.
Zurück zum Zitat Abboud Y, Samaan JS, Oh J et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology. 2023;164:978-989.e6.CrossRefPubMed Abboud Y, Samaan JS, Oh J et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology. 2023;164:978-989.e6.CrossRefPubMed
23.
Zurück zum Zitat Piciucchi M, Capurso G, Valente R et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–155.CrossRefPubMed Piciucchi M, Capurso G, Valente R et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–155.CrossRefPubMed
24.
Zurück zum Zitat Liu J, Ren ZH, Qiang H et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20:1415.CrossRefPubMedPubMedCentral Liu J, Ren ZH, Qiang H et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20:1415.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Prabhakaran D, Chaturvedi V, Shah P et al. Differences in the prevalence of metabolic syndrome in urban and rural India: a problem of urbanization. Chronic Illn. 2007;3:8–19.CrossRefPubMed Prabhakaran D, Chaturvedi V, Shah P et al. Differences in the prevalence of metabolic syndrome in urban and rural India: a problem of urbanization. Chronic Illn. 2007;3:8–19.CrossRefPubMed
26.
Zurück zum Zitat Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.CrossRefPubMed Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.CrossRefPubMed
27.
Zurück zum Zitat World Health Organization. WHO global report on trends in prevalence of tobacco smoking 2000–2025. World Health Organization, 2018. World Health Organization. WHO global report on trends in prevalence of tobacco smoking 2000–2025. World Health Organization, 2018.
28.
Zurück zum Zitat Bilano V, Gilmour S, Moffiet T et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control [published correction appears in Lancet. 2015 Jun 13;385:2354]. Lancet 2015;385:966–976.CrossRefPubMed Bilano V, Gilmour S, Moffiet T et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control [published correction appears in Lancet. 2015 Jun 13;385:2354]. Lancet 2015;385:966–976.CrossRefPubMed
29.
Zurück zum Zitat Overbeek KA, Levink IJ, Koopmann BD et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71:1152–1160.CrossRefPubMed Overbeek KA, Levink IJ, Koopmann BD et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71:1152–1160.CrossRefPubMed
30.
31.
Zurück zum Zitat Fan KM, Rimal J, Zhang P et al. Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. EClinicalMedicine. 2022;54:101673.CrossRefPubMedPubMedCentral Fan KM, Rimal J, Zhang P et al. Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. EClinicalMedicine. 2022;54:101673.CrossRefPubMedPubMedCentral
Metadaten
Titel
Epidemiology and Socioeconomic Impact of Pancreatic Cancer: An Analysis of the Global Burden of Disease Study 1990–2019
verfasst von
Daryl Ramai
Eric R. Smith
Yichen Wang
Yuting Huang
Itegbemie Obaitan
Saurabh Chandan
Banreet Dhindsa
Apostolis Papaefthymiou
John D. Morris
Publikationsdatum
21.02.2024
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08292-1

Weitere Artikel der Ausgabe 4/2024

Digestive Diseases and Sciences 4/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.